If you are having trouble viewing this email, click
here | At this point there is little doubt that Ariad is seeking to sell itself. Here are five companies that could be interested. |
| Aiach, 44, is now the CEO of the French biotech Lysogene, which has raised $30 million to date and completed an early-stage trial of a treatment which replaces the gene that’s defective in Sanfilippo patients. |
| The trial of CA-170, which dosed its first patient last week, represents the first study of an immuno-oncology pill rather than an IV. |
| According to U.S. Attorney Carmen M. Ortiz, Denmark-based BK Medical ApS, falsified records to hide payments to people unconnected with the sale of ultrasound equipment. |
| | |
| |
| Cancel Email Subscription You may change your email address, your preferences, or unsubscribe from this email at any time by visiting bizjournals.com: https://www.bizjournals.com/account/ If you need other assistance, please let us know or contact: bizjournals.com customer service, bizjournals 120 W. Morehead St., Charlotte, North Carolina 28202 The Business Journals | Latest News | Advertise | Contact Info | Subscribe to Print Edition © 2016 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this may not be reproduced, distributed, transmitted, cached or otherwise used, except with the written permission of bizjournals. |
